Ozempic: Unintended Consequences

Ozempic: Unintended Consequences

As new technologies and innovations are developed and widely implemented, a range of unintended consequences inevitably ensue. Last week, Walmart revealed that individuals purchasing weight loss medications containing semaglutide, such as Wegovy and Ozempic, at Walmart’s pharmacies have been purchasing slightly fewer groceries at its outlets. This development caused about a 2% drop in Walmart’s stock price. Other grocery retailers, fast-food chains, and sugary beverage manufacturers like McDonald’s and Coca-Cola also experienced declines in their respective share prices due to the announcement.

New innovations bring about new innovations. Ozempic, developed by Novo Nordisk, received approval from the Food and Drug Administration (FDA) in 2017 for the treatment of type-2 diabetes. Subsequently, it was observed that the drug was effective in treating individuals grappling with obesity. In 2021, Wegovy gained FDA approval specifically for obesity treatment. Wegovy and Ozempic operate as glucagon-like-peptide-1 (GPL-1) receptor agonist, essentially emulating the naturally occurring hormone GLP-1, which aids in appetite regulation and decelerates food digestion. This year, Novo Nordisk made the noteworthy discovery that their Wegovy treatment also reduces the risk of serious cardiovascular events in patients. The innovation of one drug has been able to treat people with different conditions.

As evidenced by Walmart’s recent announcement, new innovations exert influence on consumers across various dimensions. In the case of Ozempic, it was approved for treating diabetes; and subsequently observed to also treat obesity. Now, it is observed that the treatment for obesity results in a lower demand for food and beverage products.

These phenomena are highly interesting for investors:

  • ·Businesses who innovate in one product or service; but this leads to other innovations. Examples includes: Google starting as a search engines, now one of the largest advertising and content platforms in the world; Amazon starting as an on-line book stores; now one of the largest retailers in the world and a leading cloud services. Businesses that are in tune to consumers changing demands will be able to benefit from the changing landscape.

  • A positive impact on one business may negatively impact others. Retailers who have lost market share to Amazon and other online retailers; less food consumed by patients being treated for obesity.

Investors need to consistently be on the look out for these positive and negatives trends.

Novo Nordisk, Walmart, and Amazon are held in the Lunar BCI World Wide Flexible fund. They are also held by Lunar Capital’s Offshore Portfolio clients.

Key Indicators
Index / Fund / Rate
Start of Year
Last Week
This Week
% Change YTD
Index / Fund / Rate
Lunar BCI WW Flexible Fund
Start of Year
141.43
Last Week
173.87
This Week
176.38
% Change YTD
24.66% Lunar Capital increasesymbol
Index / Fund / Rate
JSE ALSI
Start of Year
73 049
Last Week
73 399
This Week
71 657 Lunar Capital stocktake arrow down
% Change YTD
-1.91% Lunar Capital stocktake arrow down
Index / Fund / Rate
NASDAQ Composite
Start of Year
10 467
Last Week
13 212
This Week
13 431 Lunar Capital increasesymbol
% Change YTD
28.32% Lunar Capital increasesymbol
Index / Fund / Rate
S&P 500
Start of Year
3 840
Last Week
4 321
This Week
4 309 Lunar Capital stocktake arrow down
% Change YTD
12.20% Lunar Capital increasesymbol
Index / Fund / Rate
Prime Lending Rate
Start of Year
10.50%
Last Week
11.75%
This Week
11.75%
% Change YTD
11.90% Lunar Capital increasesymbol
Index / Fund / Rate
USD/ZAR
Start of Year
16.98
Last Week
18.75
This Week
19.34 Lunar Capital increasesymbol
% Change YTD
13.90% Lunar Capital increasesymbol
Index / Fund / Rate
EUR/ZAR
Start of Year
18.44
Last Week
20.01
This Week
20.49 Lunar Capital increasesymbol
% Change YTD
11.12% Lunar Capital increasesymbol
Index / Fund / Rate
Brent Crude ($'barrel)
Start of Year
85.95
Last Week
93.60
This Week
84.56 Lunar Capital stocktake arrow down
% Change YTD
-1.62% Lunar Capital stocktake arrow down
Source: Iress

Click here to access your account to view statements, obtain tax certificates, add or make changes to your investments.

Our email address is: [email protected]

Disclosures
Lunar Capital (Pty) Ltd is a registered Financial Services Provider. FSP (46567)
Read our full Disclosure statement: https://lunarcapital.co.za/disclosures/
Our Privacy Notice: https://lunarcapital.co.za/privacy-policy/
The Lunar BCI Worldwide Flexible Fund Fact Sheet  can be read here.
This stocktake is prepared for the clients of Lunar Capital (Pty) Ltd. This stocktake does not constitute financial advice and is generated for information purposes only.

Share article

Latest Posts

Nike: Will they Do It?
Nike: Will they Do It?
Does Nike have what it takes to implement their turnaround vision?
Good prices and good margin, How has Costco managed it?
Cost Conscious Costco
Good prices and good margin, How has Costco managed it?
Stocktake Image _ 2024-09-13
Zara Fit Check
What is Inditex doing to position itself for the future

Lunar Capital
on Eastwave Radio

Every Wednesday, at 07h45, Sabir chats with Nazia from Eastwave Radio (92.2 fm, live stream on
www.eastwave.co.za) on investing and the markets.

eastwave-radio
Scroll to Top